Skip Nav Destination
Issues
15 January 2010
-
Cover Image
Cover Image
Glioma-associated cancer-initiating cells participate in tumor-mediated immune suppression by inhibiting effector T-cell functions by a combination of cell surface contact inhibition via B7-H1 and soluble factors including Galectin-3. Shown here are human glioma-associated cancer-initiating cells xenografted into the frontal lobe of a nude mouse that shows their ability to recapitulate many of the hallmark features of malignant gliomas including mass effect, diffuse ill-defined infiltration and tracking along white matter tracts such as the corpus callosum. Differentiation of the glioma-associated cancer-initiating cells markedly reduces their ability to mediate immune suppression. For further details, please see Wei et al on page 461 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Review
Human Cancer Biology
MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer
Maria Teresa Landi; Yingdong Zhao; Melissa Rotunno; Jill Koshiol; Hui Liu; Andrew W. Bergen; Maurizia Rubagotti; Alisa M. Goldstein; Ilona Linnoila; Francesco M. Marincola; Margaret A. Tucker; Pier Alberto Bertazzi; Angela C. Pesatori; Neil E. Caporaso; Lisa M. McShane; Ena Wang
ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer
Ilka Brigitte Petry; Esther Fieber; Marcus Schmidt; Mathias Gehrmann; Susanne Gebhard; Matthias Hermes; Wiebke Schormann; Silvia Selinski; Evgenia Freis; Holger Schwender; Marc Brulport; Katja Ickstadt; Jörg Rahnenführer; Lindsey Maccoux; Jonathan West; Heinz Kölbl; Martin Schuler; Jan Georg Hengstler
Cancer Therapy: Preclinical
Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms
Patricia A. Culp; Donghee Choi; Yongke Zhang; Johnny Yin; Pui Seto; Suzanne E. Ybarra; Mian Su; Mien Sho; Roxanne Steinle; Melanie H.L. Wong; Ferdinand Evangelista; Jennifer Grove; Marie Cardenas; Marjorie James; Eric D. Hsi; Debra T. Chao; David B. Powers; Vanitha Ramakrishnan; Robert Dubridge
Antitumor Effect of NK012, a 7-Ethyl-10-Hydroxycamptothecin–Incorporating Polymeric Micelle, on U87MG Orthotopic Glioblastoma in Mice Compared with Irinotecan Hydrochloride in Combination with Bevacizumab
Jun-ichiro Kuroda; Jun-ichi Kuratsu; Masahiro Yasunaga; Yoshikatsu Koga; Hirotsugu Kenmotsu; Takashi Sugino; Yasuhiro Matsumura
Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer
James W. Purcell; Jefferson Davis; Mamatha Reddy; Shamra Martin; Kimberly Samayoa; Hung Vo; Karen Thomsen; Peter Bean; Wen Lin Kuo; Safiyyah Ziyad; Jessica Billig; Heidi S. Feiler; Joe W. Gray; Kenneth W. Wood; Sylvaine Cases
Imaging, Diagnosis, Prognosis
Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
Riccardo Bomben; Michele Dal-Bo; Dania Benedetti; Daniela Capello; Francesco Forconi; Daniela Marconi; Francesco Bertoni; Rossana Maffei; Luca Laurenti; Davide Rossi; Maria Ilaria Del Principe; Fabrizio Luciano; Elisa Sozzi; Ilaria Cattarossi; Antonella Zucchetto; Francesca Maria Rossi; Pietro Bulian; Emanuele Zucca; Milena S. Nicoloso; Massimo Degan; Roberto Marasca; Dimitar G. Efremov; Giovanni Del Poeta; Gianluca Gaidano; Valter Gattei
A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages
Björn Engelbrekt Wahlin; Mohit Aggarwal; Santiago Montes-Moreno; Luis Francisco Gonzalez; Giovanna Roncador; Lidia Sanchez-Verde; Birger Christensson; Birgitta Sander; Eva Kimby
Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients
Hugo M. Horlings; Carmen Lai; Dimitry S.A. Nuyten; Hans Halfwerk; Petra Kristel; Erik van Beers; Simon A. Joosse; Christiaan Klijn; Petra M. Nederlof; Marcel J.T. Reinders; Lodewyk F.A. Wessels; Marc J. van de Vijver
Cancer Therapy: Clinical
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Christina M. Annunziata; Amanda J. Walker; Lori Minasian; Minshu Yu; Herbert Kotz; Bradford J. Wood; Katherine Calvo; Peter Choyke; Daniel Kimm; Seth M. Steinberg; Elise C. Kohn
A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies
Susanne M. Arnold; John J. Rinehart; Eleftheria Tsakalozou; John R. Eckardt; Scott Z. Fields; Brent J. Shelton; Philip A. DeSimone; Bryan K. Kee; Jeffrey A. Moscow; Markos Leggas
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
Joshua A. Bauer; A. Bapsi Chakravarthy; Jennifer M. Rosenbluth; Deming Mi; Erin H. Seeley; Nara De Matos Granja-Ingram; Maria G. Olivares; Mark C. Kelley; Ingrid A. Mayer; Ingrid M. Meszoely; Julie A. Means-Powell; Kimberly N. Johnson; Chiaojung Jillian Tsai; Gregory D. Ayers; Melinda E. Sanders; Robert J. Schneider; Silvia C. Formenti; Richard M. Caprioli; Jennifer A. Pietenpol
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Michael S. Gordon; Christopher J. Sweeney; David S. Mendelson; S. Gail Eckhardt; Abraham Anderson; Darrin M. Beaupre; Daniel Branstetter; Teresa L. Burgess; Angela Coxon; Hongjie Deng; Paula Kaplan-Lefko; Ian M. Leitch; Kelly S. Oliner; Lucy Yan; Min Zhu; Lia Gore
Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes
Owen A. O'Connor; Carol Portlock; Craig Moskowitz; Paul Hamlin; David Straus; John Gerecitano; Mithat Gonen; Otilia Dumitrescu; Debra Sarasohn; John Butos; Ellen Neylon; Barbara Mac-Gregor Cortelli; Susan Blumel; Andrew M. Evens; Andrew D. Zelenetz; John Wright; Brenda Cooper; Jane Winter; Julie Vose
Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy
Claude Sportès; Rebecca R. Babb; Michael C. Krumlauf; Frances T. Hakim; Seth M. Steinberg; Catherine K. Chow; Margaret R. Brown; Thomas A. Fleisher; Pierre Noel; Irina Maric; Maryalice Stetler-Stevenson; Julie Engel; Renaud Buffet; Michel Morre; Robert J. Amato; Andrew Pecora; Crystal L. Mackall; Ronald E. Gress
Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
Shana Jacobs; Elizabeth Fox; Mark Krailo; Gwen Hartley; Fariba Navid; Leonard Wexler; Susan M. Blaney; Anne Goodwin; Wendy Goodspeed; Frank M. Balis; Peter C. Adamson; Brigitte C. Widemann
Susceptibility and Prevention
Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report
Nicolas Girard; Emil Lou; Christopher G. Azzoli; Rekha Reddy; Mark Robson; Megan Harlan; Irene Orlow; Yasushi Yatabe; Khedoudja Nafa; Marc Ladanyi; Agnes Viale; Mark G. Kris; Gregory Riely; Vincent Miller; Robert J. Klein; Keitaro Matsuo; William Pao
Reduced DNA Repair Capacity for Removing Tobacco Carcinogen–Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but not Tumor Characteristics
Li-E Wang; Zhibin Hu; Erich M. Sturgis; Margaret R. Spitz; Sara S. Strom; Christopher I. Amos; Zhaozheng Guo; Yawei Qiao; Ann Marie Gillenwater; Jeffrey N. Myers; Gary L. Clayman; Randal S. Weber; Adel K. El-Naggar; Li Mao; Scott M. Lippman; Waun Ki Hong; Qingyi Wei
Highlights
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.